Adaptive Biotechnologies Corp [ADPT] stock is trading at $4.90, up 22.50%. An important factor to consider is whether the stock is rising or falling in short-term value. The ADPT shares have gain 2.51% over the last week, with a monthly amount glided 5.60%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Scotiabank started tracking the stock with Sector Outperform rating on January 05, 2023, and set its price target to $15. On December 21, 2022, upgrade upgraded it’s rating to Overweight and revised its price target to $14 on the stock. Credit Suisse started tracking the stock assigning a Underperform rating and suggested a price target of $8 on August 25, 2022. Piper Sandler initiated its recommendation with a Neutral and recommended $7.50 as its price target on June 03, 2022. JP Morgan reiterated a Overweight rating for this stock on February 16, 2022, and downed its price target to $50. In a note dated February 16, 2022, Goldman reiterated an Neutral rating on this stock and revised its target price from $54 to $21.
Adaptive Biotechnologies Corp [ADPT] stock has fluctuated between $2.28 and $6.34 over the past year. Currently, Wall Street analysts expect the stock to reach $12.33 within the next 12 months. Adaptive Biotechnologies Corp [NASDAQ: ADPT] shares were valued at $4.90 at the most recent close of the market. An investor can expect a potential return of 151.63% based on the average ADPT price forecast.
Analyzing the ADPT fundamentals
Adaptive Biotechnologies Corp [NASDAQ:ADPT] reported sales of 168.77M for the trailing twelve months, which represents a drop of -11.72%. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -1.09%, Pretax Profit Margin comes in at -1.27%, and Net Profit Margin reading is -1.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.72 and Total Capital is -0.37. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.14 points at the first support level, and at 3.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.60, and for the 2nd resistance point, it is at 6.29.
Ratios To Look Out For
For context, Adaptive Biotechnologies Corp’s Current Ratio is 3.99. On the other hand, the Quick Ratio is 3.84, and the Cash Ratio is 0.68. Considering the valuation of this stock, the price to sales ratio is 4.28, the price to book ratio is 2.99.
Transactions by insiders
Recent insider trading involved Taylor Stacy L, SVP and General Counsel, that happened on Aug 22 ’24 when 26922.0 shares were sold. Officer, STACY L TAYLOR completed a deal on Aug 22 ’24 to buy 26922.0 shares. Meanwhile, Principal Accounting Officer PISKEL KYLE sold 7727.0 shares on Mar 05 ’24.
